Our Mission

Aleta’s mission is to create cell therapeutics that provide robust and durable clinical benefit for patients suffering from advanced hematologic cancers and refractory solid tumors. Aleta’s CAR-T Engager technology incorporates potent multi-antigen targeting, optimal T cell fitness, and persistence to aggressively attack cancers. We use this technology to build programs that solve specific clinical issues, including cell therapy relapses due to antigen loss and the challenge of overcoming solid tumor heterogeneity. Our lead development program has won landmark clinical support from Cancer Research UK and will enter Phase1/2 trials in 2022.

Our Science

With our CAR-T Engager platform, we are building treatments to enhance cell therapies. Our lead candidate, ALETA-001, is focused on eliminating CD19 CAR-T relapses.

Latest News

Aleta Biotherapeutics Announces Presentation at the 25th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Aleta Biotherapeutics, a privately held immuno-oncology company focused on transforming cellular therapeutics to allow a broad spectrum of cancer indications to be targeted, today released new preclinical results at the 25th American Society of Gene & Cell Therapy Annual Meeting, held in Washington DC and in a virtual platform on May 16-19, 2022. ASGCT is the premier showcase for advances in cell and gene engineering, development and clinical translation.

The presentation featured preclinical data that advance Aleta’s programs in development for the treatment of multiple myeloma and acute myeloid leukemia. These programs leverage the company’s proprietary CAR T Engager technology – multi-antigen targeting systems designed to expand the functionality of conventional cell therapeutics.

Aleta Biotherapeutics Announces ALETA-001 Poster Presentation at the 63rd American Society of Hematology (ASH) Annual Meeting

Aleta Biotherapeutics, a privately held immuno-oncology company focused on transforming cellular therapeutics to allow a broad spectrum of cancer indications to be targeted, today released a summary of ALETA-001 preclinical results from a poster being presented at the 63rd American Society of Hematology (ASH) Annual Meeting, held in Atlanta, Georgia and in a virtual platform on December 11-14, 2021.

The presentation featured preclinical data that support the upcoming Phase 1/2 clinical trial of ALETA-001 being run in collaboration with Cancer Research UK. ALETA-001 is a multifunctional biologic for injection that contains an anti-CD20 llama VHH linked to an optimized CD19 protein and further linked to an anti-albumin llama VHH.

Get In Touch

Send message